Initial Management for Left-Sided Heart Failure

Initial Assessment

• The American Heart Association recommends assessing volume status, orthostatic blood pressure changes, weight, height, and body mass index in patients with left-sided heart failure 1, 2
• The American College of Cardiology suggests performing laboratory evaluation including complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, fasting blood glucose, lipid profile, liver function tests, and thyroid-stimulating hormone in patients with left-sided heart failure 1, 2
• The American Heart Association recommends obtaining 12-lead electrocardiogram and chest radiograph (PA and lateral) in patients with left-sided heart failure 1, 2
• Two-dimensional echocardiography with Doppler should be performed to assess left ventricular ejection fraction (LVEF), left ventricular size, wall thickness, and valve function in patients with left-sided heart failure 1, 2

Pharmacological Management

• The American College of Cardiology recommends initiating ACE inhibitors and beta-blockers in all patients with left ventricular systolic dysfunction, regardless of symptom severity 3, 4
• Beta-blockers should be introduced in a "start-low, go-slow" manner, with monitoring of heart rate, blood pressure, and clinical status after each dose titration, as recommended by the American Heart Association 3, 5
• The American College of Cardiology suggests using diuretics to manage fluid retention in patients with left-sided heart failure 6
• ACE inhibitors have a stronger evidence base than ARBs and should be preferred, according to the American College of Cardiology 3, 5
• The American Heart Association recommends monitoring renal function in patients receiving ACE inhibitors or ARBs 3, 5

Non-Pharmacological Management

• The American College of Cardiology recommends moderate sodium restriction and daily weight measurement in patients with left-sided heart failure 6
• Immunization with influenza and pneumococcal vaccines may reduce risk of respiratory infections, as suggested by the American College of Cardiology 6
• Physical activity should be encouraged, except during periods of acute decompensation, according to the American College of Cardiology 6
• The American Heart Association recommends close follow-up and patient education to detect early changes in body weight or clinical status 6

Advanced Therapies for Refractory Symptoms

• The American College of Cardiology recommends considering cardiac resynchronization therapy for patients with left ventricular ejection fraction <35% and QRS duration ≥150 ms or between 120-149 ms with mechanical dyssynchrony on echocardiography 5
• The American Heart Association suggests evaluating for implantable cardioverter-defibrillators in appropriate candidates 5

Common Pitfalls to Avoid

• The American College of Cardiology recommends avoiding underutilization of beta-blockers, especially in older adults and those with comorbidities 3, 4
• Premature switching from ACE inhibitors to ARBs without adequate trial of ACE inhibitors should be avoided, according to the American College of Cardiology 3, 5
• Inadequate monitoring of renal function and electrolytes when using ACE inhibitors, ARBs, or aldosterone antagonists should be avoided, as recommended by the American Heart Association 3, 5

Evidence‑Based Management of Chronic Systolic Heart Failure (LVEF ≤ 40%)

Pharmacologic Management

• Beta‑blocker initiation – In adults with chronic systolic heart failure, start a proven beta‑blocker (bisoprolol, carvedilol, or metoprolol succinate) at a low dose and double the dose every 2 weeks while monitoring heart rate, blood pressure, and clinical status after each increase. [High‑quality evidence] 7

• ACE‑inhibitor (or ARNI) benefit – Adding an ACE inhibitor (or sacubitril/valsartan) 1–2 weeks after beta‑blocker/SGLT2‑inhibitor initiation reduces morbidity and improves survival in this population. [High‑quality evidence] 7, 8

• Switch to ARB when ACE intolerable – Patients who experience intolerable adverse effects from ACE inhibitors should be switched to an angiotensin‑receptor blocker. 9

• Hydralazine‑nitrate combination for double intolerance – If both ACE inhibitors and ARBs are not tolerated, prescribe a combination of hydralazine and a nitrate to provide neurohormonal blockade. 7, 8

• Aldosterone antagonist indication – Initiate spironolactone or eplerenone in patients whose LVEF is < 35 % and/or who remain symptomatic (NYHA class II–IV) after earlier steps. 9

• Renal‑electrolyte monitoring with aldosterone antagonists – Close monitoring of serum potassium and renal function is required after starting an aldosterone antagonist and after any dose adjustment. 9

• Loop diuretics for congestion – Loop diuretics are essential for relieving fluid overload and controlling symptoms, although they do not confer a survival benefit. 7

Non‑Pharmacologic Management

• Supervised cardiac rehabilitation – Offering a structured, exercise‑based cardiac rehabilitation program to all stable patients reduces hospital admissions and improves long‑term quality of life. [Moderate‑quality evidence] 9

Device Therapy

• Cardiac resynchronization therapy (CRT) – Consider CRT for patients with LVEF < 35 % and a QRS duration ≥ 150 ms, or 120–149 ms with echocardiographic mechanical dyssynchrony, who remain symptomatic despite optimal medical therapy. 9

• Implantable cardioverter‑defibrillator (ICD) – Evaluate for ICD implantation in patients with LVEF < 35 % who have sustained ventricular tachycardia, inducible nonsustained VT on electrophysiology testing, or QRS ≥ 120 ms with LVEF < 30 %. 9

Monitoring Requirements

• Vital‑sign and clinical assessment after titration – After each medication dose change, assess heart rate, blood pressure, and overall clinical status to ensure tolerability. 7

Common Pitfalls to Avoid

• Under‑use of beta‑blockers in older adults and comorbid conditions – Do not withhold beta‑blockers in patients ≥ 65 years or those with peripheral vascular disease, erectile dysfunction, diabetes, interstitial lung disease, or irreversible COPD, as evidence supports benefit across these groups. 7, 8